+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ProteoMediX AG - Product Pipeline Analysis, 2019 Update

  • PDF Icon

    Company Profile

  • 24 Pages
  • August 2019
  • GlobalData
  • ID: 4455855
Summary

ProteoMediX AG (ProteoMediX) is a medical diagnostic company that identifies and develops novel biomarkers for the early detection of cancer and the personalized treatment. The company develops non-invasive diagnostic tests for the detection, prognosis, stratification, and therapy-selection of prostate cancer. Its biomarkers are discovered using a genetics-guided discovery approach and are used in detecting PI3K/PTEN cancer pathway. ProteoMediX offers proteomics technologies, which are used to analyze glycosylated proteins in prostate tissue and serum from wild-type mice and mice with prostate-specific deletion of the tumor suppressor PTEN. The company serves patients with prostate and other types of cancer. ProteoMediX is headquartered in Schlieren, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company ProteoMediX AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

ProteoMediX AG Company Overview
  • ProteoMediX AG Company Snapshot
  • ProteoMediX AG Pipeline Products and Ongoing Clinical Trials Overview
  • ProteoMediX AG – Pipeline Analysis Overview
  • ProteoMediX AG - Key Facts
  • ProteoMediX AG - Major Products and Services
  • ProteoMediX AG Pipeline Products by Development Stage
  • ProteoMediX AG Pipeline Products Overview
  • Diagnostic Test - Prostate Cancer
  • Diagnostic Test - Prostate Cancer Product Overview
  • Prostate Cancer Prognosis Assay
  • Prostate Cancer Prognosis Assay Product Overview
  • Prostate Cancer Stratification Assay
  • Prostate Cancer Stratification Assay Product Overview
  • ProteoMediX Prostate Cancer Test
  • ProteoMediX Prostate Cancer Test Product Overview
  • ProteoMediX AG - Key Competitors
  • ProteoMediX AG - Key Employees
  • ProteoMediX AG - Locations And Subsidiaries
  • Head Office

Recent Developments
  • ProteoMediX AG, Recent Developments
  • Sep 11, 2018: New publication confirms that the use of ProteoMediX proprietary blood-based biomarkers improves clinically significant prostate cancer diagnosis
  • Apr 13, 2018: Novel Biomarker Test Avoids Biopsies by Accurately Predicting High-Grade Prostate Cancer
  • Jun 21, 2017: Dr. Helge Lubenow elected as a new member to the Board of Directors
  • Mar 27, 2017: Recent Clinical Study Results of ProteoMediX' Prostate Cancer Test Presented at the 2017 Annual European Association of Urology Congress
  • Jan 13, 2017: ProteoMediX receives ISO 13485:2012 Certification
  • Sep 08, 2014: CTI supports the development of a prostate cancer risk stratification test
  • Jun 17, 2014: Harry Welten joins the Board of Directors of ProteoMediX
  • May 19, 2014: ProteoMediX adds Mark Emberton as new clinical advisor
  • Apr 26, 2013: ProteoMediX Announces Publication of Results of its Biomarkers
  • Jul 21, 2011: New Publication Proofs Prognostic Potential Of ProteoMediX' Proprietary Biomarkers

Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

List of Tables
  • ProteoMediX AG Pipeline Products and Ongoing Clinical Trials Overview
  • ProteoMediX AG Pipeline Products by Equipment Type
  • ProteoMediX AG Pipeline Products by Indication
  • ProteoMediX AG, Key Facts
  • ProteoMediX AG, Major Products and Services
  • ProteoMediX AG Number of Pipeline Products by Development Stage
  • ProteoMediX AG Pipeline Products Summary by Development Stage
  • Diagnostic Test - Prostate Cancer - Product Status
  • Diagnostic Test - Prostate Cancer - Product Description
  • Prostate Cancer Prognosis Assay - Product Status
  • Prostate Cancer Prognosis Assay - Product Description
  • Prostate Cancer Stratification Assay - Product Status
  • Prostate Cancer Stratification Assay - Product Description
  • ProteoMediX Prostate Cancer Test - Product Status
  • ProteoMediX Prostate Cancer Test - Product Description
  • ProteoMediX AG, Key Employees
  • Glossary

List of Figures
  • ProteoMediX AG Pipeline Products by Equipment Type
  • ProteoMediX AG Pipeline Products by Development Stage

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • SimplicityBio SA
  • Genedata AG
  • Quartz Bio SA